Elanco Animal Health Shares Jump 7.6% as Q3 Earnings Beat Forecasts and Company Raises 2026 Outlook

Elanco Animal Health reported Q3 2026 revenue up 11%, with gross margin expansion driven by pricing and productivity. CEO Jeff Simmons and CFO Robert VanHimbergen reaffirmed 2027 guidance, citing strong pet owner spending and product performance. They discussed growth strategies, competitive dynamics, and pipeline prospects, including Zenrelia and Befrena.

Elanco (ELAN) shares rose 9.5% after reporting Q3 2026 revenue of $1.265B, up 11% YoY, and raising full-year guidance. The company projects 2026 revenue between $5.155B-$5.18B and adjusted EPS between $1.17-$1.20. Shares are up 15.1% YTD, near a 52-week high of $26.84.

Elanco (ELAN) reported Q3 2026 earnings, exceeding guidance with 9% revenue growth. Key drivers were International Pet Health (up 17%) and US Pet Health (up 13%), led by products like Zenrelia and Credelio Cuatro. Innovation revenue reached $328M, up 40% YoY. The company raised full-year innovation revenue targets to $1.275B and increased overall guidance. Zenrelia achieved record market share in the US and is nearing blockbuster status internationally.

Elanco reported 3Q 2026 revenue of $1.27B, up 11% YoY, and net income of $18M, reversing a prior-year loss. Pet Health and Farm Animal sales grew, with improved margins from pricing and product mix. EPS was $0.04, up from a loss of $0.07.

Elanco Animal Health (ELAN) reported Q3 2026 net income of $18M ($0.04 EPS), up from a $34M loss last year. Revenue rose 11% to $1.27B. Adjusted EBITDA increased 23% to $243M. The company raised full-year 2026 guidance and provided 2027 outlook. Pre-market shares fell 3.55% to $22.83.

Elanco reported Q3 2026 revenue of $1.27 billion, exceeding estimates by 4.8%. Adjusted EPS was $0.27, a 32.8% beat. The company raised full-year guidance for revenue, EPS, and EBITDA. Operating margin improved to 18% from 0.2% year-on-year.